Aditxt Inc is a biotech company focused on enhancing the immune system through innovative technologies designed to promote immune tolerance. The company seeks to develop therapies that can help manage and treat immune-related diseases by leveraging its proprietary platform to create customized solutions. Aditxt's research and development efforts aim to address a range of immunological disorders, potentially transforming the landscape of immunotherapy and improving patient outcomes through better immune system management. Read More
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Aditxt (NASDAQ: ADTX), a social innovation platform accelerating promising health innovations, will implement a 1-for-113 reverse stock split of its common stock effective at the opening of trading on Nov. 3, 2025. The stock will continue trading under the symbol ADTX. Following the split, every 113 shares of issued and outstanding common stock will convert into one share, rounding up fractional shares. The move, approved by stockholders on Sept. 23, 2025, is intended to help the Company regain compliance with Nasdaq’s minimum bid price requirement.
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market on November 3, 2025, the Company’s common stock will trade on a post-split basis under the same symbol ADTX. The reverse stock split was approved by the Company’s stockholders at the reconvened annual meeting held on September 23, 2025, with the final ratio determined by the Company’s board of directors.
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Stay updated with the latest market activity on Tuesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health innovations, announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic (R) Endometriosis Test (MET(TM)), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET’s performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery. The first site, Dedicated to Women OB/GYN in Dover, Del., has begun enrollment. Pearsanta President Chris Mitton said the milestone supports validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis.
Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has begun enrollment in their prospective clinical study evaluating the Mitomic® Endometriosis Test (MET™), a novel blood-based diagnostic designed to aid in the early detection of endometriosis.
$7.3 Million Fuels Upcoming Launches of Winnie & Friends, Stan Lee Universe , and Bitcoin Brigade as TOON Strengthens Its Global Streaming, Licensing, and Franchise Expansion
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
